Compare CBAN & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBAN | ENTA |
|---|---|---|
| Founded | 1975 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.6M | 374.6M |
| IPO Year | 1995 | 2012 |
| Metric | CBAN | ENTA |
|---|---|---|
| Price | $19.47 | $14.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | ★ 320.6K | 100.1K |
| Earning Date | 04-22-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 16.91 | ★ 29.93 |
| EPS | ★ 1.59 | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $35.41 | $7.76 |
| Revenue Next Year | $4.84 | N/A |
| P/E Ratio | $12.47 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $14.63 | $4.96 |
| 52 Week High | $21.61 | $17.15 |
| Indicator | CBAN | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 61.80 |
| Support Level | $19.12 | $13.75 |
| Resistance Level | $21.21 | $15.37 |
| Average True Range (ATR) | 0.51 | 0.64 |
| MACD | -0.16 | 0.06 |
| Stochastic Oscillator | 6.90 | 81.88 |
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.